| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | ||||||||||
Total revenues | ||||||||||
26,742 | 477,053 | 12,268 | 14,987 | - | - | - | - | - | - | - |
Research and development | ||||||||||
- | - | - | - | 8,175 | 3,139 | 5,519 | 8,970 | 12,725 | 19,215 | 13,811 |
Operating expenses | ||||||||||
Cost of sales and supportive services | ||||||||||
1,782 | 95,268 | 0 | 0 | - | - | - | - | - | - | - |
Selling, general and administrative | ||||||||||
13,252 | 12,879 | 12,303 | 13,713 | 10,582 | 12,646 | 13,119 | 10,967 | 23,931 | 8,130 | 7,533 |
Research and development | ||||||||||
13,303 | 13,016 | 16,679 | 19,710 | 13,130 | 10,707 | 13,785 | 18,213 | 18,367 | 22,658 | 17,423 |
Patent expenses | ||||||||||
726 | 789 | 909 | 909 | 1,009 | 987 | 1,421 | 1,883 | 1,808 | 1,148 | 734 |
Litigation expense | ||||||||||
- | - | - | - | 14,407 | 188,465 | - | 442 | - | - | - |
Lease termination | ||||||||||
0 | 0 | -1,225 | 0 | 0 | - | - | - | - | - | - |
Interest on PharmAthene liability | ||||||||||
- | - | - | 11,668 | 0 | 0 | - | - | - | - | - |
Restructuring charges | ||||||||||
- | - | - | - | - | - | - | 0 | 0 | - | - |
Total operating expenses | ||||||||||
29,064 | 121,954 | 31,118 | 46,002 | 39,129 | 212,806 | 29,035 | 31,506 | 44,107 | 31,938 | 25,690 |
Operating (loss) income | ||||||||||
-2,322 | 355,099 | -18,849 | -31,014 | -30,953 | -209,667 | -23,516 | -22,535 | -31,381 | -12,722 | -11,878 |
Gain (loss) from change in fair value of warrant liability | ||||||||||
5,091 | -6,922 | -4,738 | -894 | - | - | - | - | - | - | - |
Decrease (increase) in fair value of common stock warrants | ||||||||||
- | - | - | - | - | - | - | -804 | -24,436 | 38,110 | 7,522 |
Interest expense | ||||||||||
15,769 | 15,478 | 14,758 | 2,395 | 266 | 455 | 1,207 | 172 | 0 | 0 | - |
Loss from change in fair value of warrant liability | ||||||||||
- | - | - | - | 0 | -313 | - | - | - | - | - |
Backstop fee | ||||||||||
- | - | - | 1,764 | 0 | 0 | - | - | - | - | - |
Other income, net | ||||||||||
2,822 | 78,940 | 16 | 102 | 42 | 1 | 1 | 0 | 13 | 659 | 1 |
Reorganization items, net | ||||||||||
- | - | - | 3,716 | 7,811 | 2,126 | 0 | 0 | - | - | - |
(Loss) income before income taxes | ||||||||||
-10,178 | 411,639 | -38,329 | -39,684 | -38,989 | -211,934 | -24,795 | -21,903 | -6,932 | -50,173 | -19,400 |
Benefit (provision) for income taxes | ||||||||||
-2,937 | -10,168 | -2,093 | 13 | 461 | 53,528 | -7,618 | -7,844 | -36,031 | 175 | 0 |
Net and comprehensive (loss) income | ||||||||||
-7,241 | 421,807 | -36,235 | -39,697 | -39,451 | -265,463 | -17,177 | -14,059 | 29,099 | -50,348 | -19,400 |
Loss per share: basic and diluted | ||||||||||
- | - | - | - | -0.73 | -4.97 | - | - | - | - | - |
Weighted average shares outstanding: basic and diluted | ||||||||||
- | - | - | - | 53,777 | 53,419 | - | - | - | - | - |
Basic (loss) income per share (in dollars per share) | ||||||||||
-0.09 | 5.28 | -0.46 | -0.69 | - | - | - | -0.27 | 0.57 | -1.12 | -0.52 |
Diluted (loss) per share (in dollars per share) | ||||||||||
-0.15 | 5.18 | -0.46 | -0.69 | - | - | - | -0.27 | 0.09 | -1.12 | -0.52 |
Weighted average shares outstanding: basic (in shares) | ||||||||||
81,031 | 79,923 | 78,874 | 57,188 | - | - | - | 51,639 | 50,929 | 45,151 | 37,463 |
Weighted average shares outstanding: diluted (in shares) | ||||||||||
82,175 | 82,708 | 78,874 | 57,188 | - | - | - | 51,639 | 54,061 | 45,151 | 37,463 |
Net income (loss) | ||||||||||
-7,241 | 421,807 | -36,235 | -39,697 | -39,451 | - | - | - | 29,099 | -50,348 | -19,400 |
Change in net unrealized gain (loss) on short-term investments | ||||||||||
- | - | - | - | - | - | - | - | -4 | 4 | - |
Comprehensive income (loss) | ||||||||||
- | - | - | - | - | - | - | - | 29,095 | -50,344 | - |
Product sales and supportive services | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | ||||||||||
11,190 | 468,918 | 0 | 0 | - | - | - | - | - | - | - |
Research and development | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | ||||||||||
15,552 | 8,135 | 12,268 | 14,987 | - | - | - | - | - | - | - |